Introduction
============

Ovarian cancer (OVC) is one of the most frequently occurring types of gynecological cancer, with 204,000 new cases identified each year and a five-year survival rate of 44% for all stages of cancer development ([@b1-ol-08-02-0566]--[@b4-ol-08-02-0566]). More than 70% of OVC cases are identified in the late stages of cancer (stage III or IV according to the International Federation of Gynecology and Obstetrics standard) ([@b2-ol-08-02-0566]). Despite improvements in anticancer therapeutic methods, the mortality rate of OVC has not decreased over the past 20 years due to difficulties in screening early stages of the disease ([@b5-ol-08-02-0566]). Current diagnostic methods include pelvic examination, ultrasonograms, blood tests and tissue examination ([@b6-ol-08-02-0566],[@b7-ol-08-02-0566]); however, these methods have several limitations, including their inability to diagnose OVC at an early stage or to detect invasiveness. Thus, early and easy-to-use diagnostic methods for OVC are required in order to increase the survival rate of patients with OVC.

Several previous studies have investigated the use of serological markers to accurately detect OVC. Such markers include cancer antigen (CA) 125, human epididymis protein 4 (HE4), and macrophage colony-stimulating factor (M-CSF) ([@b5-ol-08-02-0566],[@b8-ol-08-02-0566],[@b10-ol-08-02-0566]). Serum CA125 and HE4 concentrations have been used as markers for OVC using radioimmunoassay ([@b6-ol-08-02-0566],[@b9-ol-08-02-0566],[@b10-ol-08-02-0566]). Furthermore, 70% of patients with OVC with various OVC cell lines have high serum levels of M-CSF ([@b11-ol-08-02-0566]). While M-CSF is a monocyte-specific cytokine for proliferation and differentiation, it also acts as a growth factor for certain epithelial cancers in an autocrine and paracrine manner ([@b12-ol-08-02-0566]). However, these markers lack accuracy and have difficulty in early diagnosis. For example CA125 was discovered 20 years ago and has been used widely as an OVC marker since ([@b13-ol-08-02-0566]). However, CA125 has low specificity and sensitivity during the early stages of OVC ([@b6-ol-08-02-0566],[@b9-ol-08-02-0566],[@b14-ol-08-02-0566]), thus an ideal marker has yet to be elucidated.

The present study profiled low-mass metabolic compounds in methanol/chloroform extracts obtained from the sera of patients with OVC and healthy controls using matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometry and identified two molecules using tandem mass spectrometry (MS/MS) analysis. The present study identified a differential pattern of lysophosphatidylcholine (LPC) (16:0) and L-homocysteic acid (HCA) in patients with OVC, and discusses the advantages of profiling low-mass metabolic compounds for screening OVC.

Materials and methods
=====================

Serum from patients with OVC
----------------------------

All participants provided written informed consent and the study protocol was approved by the Institutional Review Board of the Ewha Womans University (Seoul, Korea). A total of 142 patients and 100 control participants were enrolled in the present study ([Table I](#tI-ol-08-02-0566){ref-type="table"}).

MALDI-TOF analysis for collecting low-mass ions (LMIs) in serum
---------------------------------------------------------------

Four times volume of methanol/chloroform (2:1; v/v) was incubated with 25 μl serum for 10 min at room temperature subsequent to vortexing. The solution was centrifuged at 6,000 × g for 10 min at 4°C. The supernatant was then dried in a concentrator for 1 h and resolved in 30 μl 50% acetonitrile/0.1% trifluoroacetic acid (TFA) using a vortex for 30 min.

Methanol/chloroform extract was mixed (1:12; v/v) with an α-cyano-4-hydroxycinnamic acid solution in 50% acetonitrile/0.1% TFA. A total of 1 μl of the solution was then spotted on the MALDI target for analysis. Individual mass spectra from the serum extracts of the patients with OVC were obtained using a 4700 Proteomics Analyzer (Ab Sciex, Framingham, MA, USA). The mass-spectral data represent the average of 20 accumulated spectra. All individual peak areas were normalized to the total area up to 2,500 m/z. To minimize experimental error, variable factors including focus mass, laser intensity, target plate and data acquisition time were tested. The ideal focus mass and laser intensity were fixed at 500 m/z and 5,000, respectively ([@b15-ol-08-02-0566]). With the fixed focus mass and laser intensity, one sample was analyzed six times under the different extraction and data acquisition times.

LMI selection and statistical analysis
--------------------------------------

All MALDI mass spectra, formatted as t2d files, were analyzed using MarkerView™ software, version 1.2 (Applied Biosystems/MDS Sciex, Toronto, ON, Canada). The optimized parameters used to compare LMI mass peaks in the serum extracts obtained from the patients with OVC were as follows: Mass tolerance, 100 ppm; minimum required response, 100; maximum number of peaks, 5000; and normalization, by total area sums. Subsequent to collecting the data using MALDI mass spectra, principal component analysis-discriminant analysis (PCA-DA) and t-tests were used to select LMIs with differential peak intensities in serum extracts from patients with OVC.

Measurement of HCA in serum
---------------------------

The level of HCA in the sera was measured using an ELISA kit (Cusabio Biotech, Co., Ltd., Wuhan, China) according to the manufacturer's instructions.

Measurement of LPC (16:0) in serum
----------------------------------

A nanoflow high-performance liquid chromatography instrument (Easy nLC; Thermo Scientific, Inc., Waltham, MA, USA) was coupled to an LTQ mass spectrometer (Thermo Scientific, Inc.). A PepMap^®^ RSLC, C18, 2 μm, 100 Å analytical column (50 cm; inner diameter, 75 μm; Dianex Corporation, Sunnyvale, CA, USA) was used. Reversed phase chromatography was performed using a binary buffer system consisting of 0.1% formic acid (buffer A) and acetonitrile in 0.1% formic acid (buffer B). The sample was separated using a linear gradient of 3--50% buffer B at a flow rate of 300 nl/min. The gradient time was 90 min and the total run time for the liquid chromatography MS/MS was 120 min. The extracted LPC was analyzed using the selected reaction monitoring (SRM) mode. The SRM transitions for the LPC lipid were set to m/z 496.4 to 183.96 and m/z 496.4 to 478.33. The SRM data were acquired within fragment ion mass ± 2 m/z and each SRM transition and respective retention time was validated for specific LPC. Data were processed through integrating the appropriate peaks for LPC, followed by comparing the calculated peak areas using two-paired t-tests.

Statistical analysis
--------------------

Between-group differences were calculated using the student's t-test and within-group correlations were calculated using Spearman's rank correlation coefficient. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Differential LMIs in methanol/chloroform extracts from the sera of patients with OVC
------------------------------------------------------------------------------------

Data (m/z and mass peak intensity) regarding the LMIs with mostly \<1,000 m/z collected from the sera extracts of 100 healthy control individuals and 142 patients with OVC were used in the PCA-DA in order to determine whether differential LMI patterns exist in the sera of patients with OVC. Supervised PCA-DA using LMI data obtained from six repeats of MALDI-TOF analysis discriminated the patients with OVC from the control individuals ([Fig. 1](#f1-ol-08-02-0566){ref-type="fig"}).

Selection and identification of LMIs showing a differential pattern in patients with OVC
----------------------------------------------------------------------------------------

Weighting factors (loading value) for all individual LMIs were calculated using PCA-DA ([Fig. 2](#f2-ol-08-02-0566){ref-type="fig"}). LMIs which consistently exhibited higher weighting factors in six different PCA-DA analyses were selected. Despite slight mass shifting, LMIs with 184.05 and 496.30 m/z showed strong discriminating power for OVC screening ([Fig. 2](#f2-ol-08-02-0566){ref-type="fig"}).

In order to identify LMIs with 184.05 and 496.30 m/z, candidate metabolites within ± 0.05 m/z difference were identified using the Human Metabolome Database (HMDB). Ten candidate metabolites with 184.05±0.05 m/z were identified ([Table II](#tII-ol-08-02-0566){ref-type="table"}). Among the candidate metabolites, the metabolic description of HCA in the HMDB was most correlated with OVC, and LPC (16:0) was the only metabolite with 496.30±0.05 m/z ([Table II](#tII-ol-08-02-0566){ref-type="table"}). The LMI with 496.30 m/z on the mass spectrum ([Fig. 3A](#f3-ol-08-02-0566){ref-type="fig"}) was further analyzed using MS/MS analysis and was identified to be LPC (16:0) through comparing the MS/MS spectrum of lipid compounds ([Fig. 3B](#f3-ol-08-02-0566){ref-type="fig"}).

Differential level of HCA and LPC (16:0)
----------------------------------------

The level of HCA was assessed in 63 control participants and 25 patients with OVC ([Table III](#tIII-ol-08-02-0566){ref-type="table"}). Due to insufficient amounts of sera, HCA was not detected in 59/63 of the controls, but the majority of cases of OVC (16/25) exhibited significantly higher levels of HCA, with the mean HCA concentration in the sera of the control individuals being 0.16 nmol/ml compared with 0.60 nmol/ml in the patients with OVC (P\<0.001; [Fig. 4A](#f4-ol-08-02-0566){ref-type="fig"}). At the cutoff of 10 nmol/ml, the sensitivity and specificity of HCA were 64.0 and 96.9%, respectively; thus, HCA may have potential for OVC screening ([Table III](#tIII-ol-08-02-0566){ref-type="table"}).

LPC (16:0) was detected as an LMI with either 183.96 or 478.33 m/z in LC-MS/MS analysis ([Fig. 5A](#f5-ol-08-02-0566){ref-type="fig"}). A sufficient amount of sera was obtained from 19 control individuals and 20 patients with OVC to quantify the level of LPC (16:0) and peak areas of 183.96 and 478.33 m/z were determined ([Table IV](#tIV-ol-08-02-0566){ref-type="table"}). The peak area was variable depending on the individual samples, but the level of LPC (16:0), represented by peak areas of 183.96 and 478.33 m/z, was observed to be lower in the sera of patients with OVC compared with that of the controls (P=0.0515 and 0.0508, respectively; [Fig. 5B](#f5-ol-08-02-0566){ref-type="fig"}).

Clinicopathological relevance of LPC (16:0) and HCA in OVC
----------------------------------------------------------

Increased LPC (16:0) was found to be significantly correlated with tumor grade (P=0.045). Although not statistically significant, possibly due to the small number of samples, HCA and LPC (16:0) were found to be correlated with stage and tumor histology (data not shown).

Discussion
==========

Despite previous investigations, a diagnostic marker for the early diagnosis of OVC has yet to be elucidated. Previous markers which have been used for OVC, including CA125 and HE4, only detected OVC at the late stages of cancer development and lacked efficiency during early tumor growth ([@b13-ol-08-02-0566],[@b14-ol-08-02-0566]).

Metabolic compounds are detected as LMIs in mass spectrometry. Our previous study showed an example of LMI profiling for cancer screening ([@b15-ol-08-02-0566]). However, at present, the dynamic status of metabolic compounds in the blood is poorly understood. Metabolic compounds in the blood are capable of showing disease status; therefore, profiling LMIs may be useful not only for understanding cancer, but also for identifying biomarkers. Furthermore, recent mass technology, including MALDI-TOF and liquid chromatography-MS/MS, has been found to provide extremely precise and accurate data on LMIs. Therefore, the present study aimed to profile LMIs in serum extracts to assess whether such profiling is capable of discriminate OVC. PCA-DA results showed that the profile of LMIs discriminated OVC ([Fig. 1](#f1-ol-08-02-0566){ref-type="fig"}). Only one control case was assigned as OVC over the six experimental repeats ([Fig. 1](#f1-ol-08-02-0566){ref-type="fig"}), allowing the LMIs with a significant effect of discriminating OVC to be selected ([Fig. 2](#f2-ol-08-02-0566){ref-type="fig"}). Two metabolic compounds were identified and quantified: HCA and LPC (16:0) ([Figs. 3](#f3-ol-08-02-0566){ref-type="fig"}--[5](#f5-ol-08-02-0566){ref-type="fig"}).

HCA has been reported to affect the oxidation of homocysteinethiolactone to sulfated glycosaminoglycans in cartilage ([@b16-ol-08-02-0566]). The free base of homocysteinethiolactone has been found to induce carcinogenesis in a mouse model, thus abnormal homocysteine metabolism may be associated with carcinogenesis ([@b16-ol-08-02-0566]). Dysregulated levels of HCA have not been reported in cancers, although markedly increased HCA has been detected in the cerebrospinal fluid of patients with lymphoma treated with methtrexate ([@b17-ol-08-02-0566],[@b18-ol-08-02-0566]). In the present study, the profiling of LMIs revealed that the level of HCA was different in the serum of patients with OVC compared with healthy control individuals, which was shown through the quantification of HCA in the sera of the controls and the patients with OVC ([Fig. 4](#f4-ol-08-02-0566){ref-type="fig"} and [Table III](#tIII-ol-08-02-0566){ref-type="table"}). HCA was not detected in the majority of the control participants, but many of the patients with OVC (16/25) showed significantly higher HCA levels ([Table III](#tIII-ol-08-02-0566){ref-type="table"}). At the cutoff of 10 nmol/ml, the sensitivity and specificity of HCA were 64.0 and 96.9%, respectively. The biological implications of upregulated HCA in the sera of patients with OVC has yet to be elucidated and the level of HCA in other types of cancer has yet to be reported. However, the present study found that HCA has strong potential for OVC screening.

The level of LPC in the blood of patients with cancer varies depending on the type of cancer, with LPC found to be decreased in breast cancer ([@b19-ol-08-02-0566]) and increased in hepatocellular carcinoma ([@b20-ol-08-02-0566]). In the present study, LPC (16:0) was observed to be decreased in the serum of patients with OVC ([Fig. 5](#f5-ol-08-02-0566){ref-type="fig"}). LPC acts as a bioactive mediator in wound healing and inflammation ([@b21-ol-08-02-0566]), but also has a role in the progression of OVC ([@b22-ol-08-02-0566]) and lung cancer ([@b23-ol-08-02-0566]). LPC has many subtypes, and each subtype has a different length of carbon chain. Although the role of each LPC subtype has yet to be elucidated, in the present study, LPC (16:0) was found to be correlated with tumor grade in patients with OVC (P=0.045).

In conclusion, the present study demonstrated that LMI profiling may be a powerful tool to obtain valuable data on metabolic compounds, as well as to identify biomarkers for cancer screening. Despite the lack of explanation for the pathological changes in HCA and LPC (16:0) in the sera of patients with OVC, the findings of the present study demonstrate that HCA is a powerful serological biomarker for OVC screening. In the present study, LPC alone was not helpful to increase the discriminating power of HCA; however, with the identification of other candidate metabolites in the future, HCA has the potential to be used in multi-biomarker OVC screening.
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![PCA-DA of the sera of 142 patients with OVC and 100 healthy controls. Methanol/chloroform extracts from the sera of 142 patients with OVC and 100 healthy controls were used for MALDI-TOF analysis. LMI data (m/z and mass peak intensity) from the extracts was obtained using MALDI-TOF analysis six times. The intensities of all of the individual LMIs were normalized using the 'total peak area sums'. The m/z and normalized intensity of LMI was used in PCA-DA. Classification results of PCA-DA repeated six times reveal that the pattern of LMI in the sera of the patients with OVC was different to that of the controls. PCA-DA, principal component analysis-discriminant analysis; OVC, ovarian cancer; MALDI-TOF, matrix-assisted laser desorption/ionization-time-of-flight; LMI, low-mass ion; Cont, control.](OL-08-02-0566-g00){#f1-ol-08-02-0566}

![Selection of LMIs with higher weighting factors. Weighting factors (or loading) for individual LMIs were calculated using principal component analysis-discriminant analysis. LMIs showing a higher weighting factor in each independent analysis were selected for further identification and validation. There was a slight mass shifting in repeated matrix-assisted laser desorption/ionization-time-of-flight analyses. LMIs with 184.05 and 496.30 m/z showed strong and constant discriminating power for ovarian cancer screening. LMI, low-mass ion.](OL-08-02-0566-g01){#f2-ol-08-02-0566}

![Identification of LMIs with 496.30 m/z. (A) Mass peak pattern of an LMI with 496.30 m/z on mass spectra. (B) MS/MS analysis for the identification of an LMI with 496.30 m/z. The MS/MS spectrum of the LMI with 496.30 m/z was identical to that of LPC (16:0). LMI, low-mass ion; MS/MS, tandem mass spectrometry; LPC, lysophosphatidylcholine; OVC, ovarian cancer.](OL-08-02-0566-g02){#f3-ol-08-02-0566}

![HCA is significantly increased in the sera of the patients with OVC. (A) Mass peak pattern of a low-mass ion with 184.05 m/z on mass spectra. (B) Increase in HCA in patients with OVC compared with the control participants. HCA was not detected in the majority of the control participants. HCA was found to be significantly increased in the sera of the patients with OVC (P\<0.001). HCA, L-homocysteic acid; OVC, ovarian cancer; MS, mass spectrometry.](OL-08-02-0566-g03){#f4-ol-08-02-0566}

![Decreased level of LPC (16:0) in the sera of patients with OVC. The level of LPC (16:0) was assessed through integrating the appropriate peaks for LPC, followed by calculating the ratio of the peak areas. (A) Extracted ion chromatogram of LPC (16:0) in the sera of the control participants and the patients with OVC. Peak areas at 183.96 and 478.33 m/z indicated the concentration of LPC (16:0). (B) The peak area of LPC (16:0) at 183.96 and 478.33 m/z. The peak area of LPC (16:0) with either 183.96 or 478.33 m/z was decreased in the sera of the patients with OVC compared with the controls, but was not significantly different (P=0.0515 and P=0.0508, respectively). LPC, lysophosphatidylcholine; OVC, ovarian cancer; RT, retention time; AA, peak area counts; SN: signal-to-noise ratio.](OL-08-02-0566-g04){#f5-ol-08-02-0566}

###### 

Characteristics of the patients with ovarian cancer and the control participants included in the present study.

  Parameter            Ovarian cancer (n=142)   Control (n=100)
  -------------------- ------------------------ -----------------
  Age, mean ± SD       52±13                    51±13
  Stage, n (%)                                  
   IA                  37 (26.1)                \-
   IB                  2 (1.4)                  \-
   IC                  12 (8.5)                 \-
   IIA                 0 (0.0)                  \-
   IIB                 1 (0.7)                  \-
   IIIA                0 (0.0)                  \-
   IIIB                1 (0.7)                  \-
   IIIC                77 (54.2)                \-
   IV                  12 (8.5)                 \-
  Histology, n (%)                              
   Serous              90 (63.4)                \-
   Mucinous            23 (16.2)                \-
   Endometrioid        8 (5.6)                  \-
   Clear cell          11 (7.7)                 \-
   Transitional cell   7 (4.9)                  \-
   Mixed               3 (2.1)                  \-
  Grade, n (%)                                  
   Mild                24 (16.9)                \-
   Moderate            35 (24.6)                \-
   Severe              83 (58.5)                \-

SD, standard deviation.

###### 

Candidate metabolites with H^+^ adducts in human metabolome database.

  Compound                           Name                                                  Adduct   Adduct MW (Da)   Compound MW (Da)   Delta
  ---------------------------------- ----------------------------------------------------- -------- ---------------- ------------------ ----------
  Metabolites with 184.05±0.05 m/z                                                                                                      
   HMDB00017                         4-Pyridoxic acid                                      M+H      184.06043        183.05316          0.010434
   HMDB02205                         L-Homocysteic acid                                    M+H      184.02742        183.02014          0.022581
   HMDB11657                         2,6-Diamino-4-hydroxy-5-N- ethylformamidopyrimidine   M+H      184.08290        183.07563          0.032901
   HMDB33141                         2-Amino-α-carboline                                   M+H      184.08692        183.07965          0.036923
   HMDB29723                         Saccharin                                             M+H      184.00629        182.99901          0.043710
   HMDB02832                         Methylnoradrenaline                                   M+H      184.09682        183.08954          0.046819
   HMDB15652                         Levonordefrin                                         M+H      184.09682        183.08954          0.046819
   HMDB00819                         Normetanephrine                                       M+H      184.09682        183.08954          0.046819
   HMDB29455                         Ginkgotoxin                                           M+H      184.09682        183.08954          0.046819
   HMDB00068                         Epinephrine                                           M+H      184.09682        183.08954          0.046819
  Metabolites with 496.30±0.05 m/z                                                                                                      
   HMDB10382                         LPC (16:0)                                            M+H      496.33977        495.33249          0.039765

LPC, lysophosphatidylcholine.

###### 

L-homocysteic acid levels in the sera of 63 control participants and 25 patients with OVC.

  Control      OVC                                                          
  ------------ ------- ------------ -------- ------------ -------- -------- ---------
  Control 01   0.000   Control 26   0.000    Control 51   0.000    OVC 01   25.991
  Control 02   0.000   Control 27   0.000    Control 52   0.000    OVC 02   0.000
  Control 03   0.000   Control 28   0.000    Control 53   48.750   OVC 03   109.620
  Control 04   0.000   Control 29   0.000    Control 54   0.000    OVC 04   0.000
  Control 05   0.000   Control 30   0.000    Control 55   0.000    OVC 05   20.037
  Control 06   0.000   Control 31   0.000    Control 56   0.000    OVC 06   0.000
  Control 07   0.000   Control 32   0.000    Control 57   0.000    OVC 07   0.000
  Control 08   0.000   Control 33   0.000    Control 58   0.000    OVC 08   0.000
  Control 09   0.000   Control 34   0.000    Control 59   0.000    OVC 09   116.759
  Control 10   0.000   Control 35   0.000    Control 60   0.000    OVC 10   79.676
  Control 11   0.000   Control 36   0.111    Control 61   0.000    OVC 11   61.083
  Control 12   0.000   Control 37   0.000    Control 62   0.000    OVC 12   172.352
  Control 13   0.000   Control 38   0.000    Control 63   0.000    OVC 13   286.398
  Control 14   0.000   Control 39   0.000                          OVC 14   203.306
  Control 15   0.000   Control 40   0.000                          OVC 15   0.000
  Control 16   0.000   Control 41   0.000                          OVC 16   175.713
  Control 17   0.000   Control 42   0.000                          OVC 17   175.676
  Control 18   0.000   Control 43   0.000                          OVC 18   74.824
  Control 19   4.981   Control 44   0.000                          OVC 19   133.407
  Control 20   0.000   Control 45   49.750                         OVC 20   344.787
  Control 21   0.000   Control 46   0.000                          OVC 21   206.537
  Control 22   0.000   Control 47   0.000                          OVC 22   0.000
  Control 23   0.000   Control 48   0.000                          OVC 23   0.000
  Control 24   0.000   Control 49   0.000                          OVC 24   72.565
  Control 25   0.000   Control 50   0.000                          OVC 25   0.000

OVC, ovarian cancer; Conc., concentration.

###### 

Level of peak area in the sera of 19 control participants and 25 patients with OVC.

  Control      OVC                                
  ------------ -------- -------- -------- ------- --------
  Control 01   177013   376781   OVC 01   14153   30741
  Control 02   69756    137502   OVC 02   5859    13745
  Control 03   124532   272566   OVC 03   7971    15462
  Control 05   25420    66997    OVC 04   8396    19590
  Control 06   54801    128622   OVC 05   20228   53475
  Control 07   37451    84449    OVC 06   16271   39552
  Control 08   83913    172936   OVC 07   32559   69217
  Control 09   24680    64998    OVC 08   25213   60890
  Control 10   24203    53327    OVC 09   12003   30286
  Control 11   154157   376840   OVC 10   26121   59037
  Control 12   22627    51433    OVC 11   33905   51453
  Control 13   48125    102808   OVC 12   51453   115718
  Control 14   52038    109721   OVC 13   40846   87236
  Control 15   45143    104486   OVC 14   68258   149730
  Control 16   10764    24637    OVC 15   49476   114076
  Control 17   4301     10910    OVC 16   53280   132663
  Control 18   6538     15969    OVC 17   49151   109521
  Control 19   5664     8595     OVC 18   40636   84156
  Control 20   1894     3979     OVC 19   35516   78462
                                 OVC 20   59084   130141
                                 OVC 21   38533   80979
                                 OVC 22   14389   31289
                                 OVC 23   7779    15915
                                 OVC 24   35065   83313
                                 OVC 25   12879   29815

OVC, ovarian cancer.
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